VTGN Investor Alert: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics Investors of the Securities Class Action Lawsuit Deadline on March 16, 2026

Core Viewpoint - The complaint alleges that Vistagen Therapeutics and its executives violated federal securities laws by making false or misleading statements and failing to disclose material adverse facts regarding its Phase 3 PALISADE-3 trial study of fasedienol, which is being developed for the acute treatment of social anxiety disorder [2] Group 1 - The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class, who directs and oversees the litigation on behalf of the putative class [3] - Any member of the putative class may move the Court to serve as lead plaintiff or may choose to remain an absent class member without affecting their ability to share in any recovery [3] Group 2 - Faruqi & Faruqi, LLP encourages anyone with information regarding Vistagen's conduct to contact the firm, including whistleblowers, former employees, and shareholders [4]